You are here: Home » International » News » Companies
Business Standard

US court denies Amgen's request for preliminary injunction against Cipla

Preliminary injunction is a court order made in the early stages of a lawsuit that prohibits the parties from doing an act in order

Press Trust of India  |  New Delhi 

Cipla, Cipla logo, Cipla headquarters
Photo: Reuters

on Friday said the has denied Amgen Inc's request for to stop Cipla's continued sale of its generic cinacalcet hydrochloride tablets in the US market.

is a court order made in the early stages of a lawsuit that prohibits the parties from doing an act in order to preserve the status quo until the trial is over and the court has issued a ruling or judgment.

The company had announced a phased launch of generic cinacalcet hydrochloride tablets, used in the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis, in the US market in a regulatory filing in March this year.

The launch, however, is a subject of ongoing litigation, it had added.

"... Chief Judge Stark of the denied Amgen, Inc's request for to stop Cipla's continued sale of its generic cinacalcet hydrochloride tablets 30mg, 60mg, 90mg in the USA," said in a filing to BSE.

Cipla's cinacalcet hydrochloride tablets in the strengths of 30mg, 60mg and 90mg are generic versions of Sensipar, a branded drug marketed by Amgen Inc.

Shares of were trading at Rs 565.75 per scrip on the BSE, up 0.16 per cent from its previous close.

First Published: Fri, May 03 2019. 14:45 IST
RECOMMENDED FOR YOU